Verdad Advisers’s Monopar Therapeutics MNPR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$670K Buy
+8,409
New +$902K 0.72% 45

Other funds holding MNPR

Verdad Advisers's MNPR Position: Q3 2026 in Review

Verdad Advisers opened a new position in Monopar Therapeutics (MNPR) in Q3 2026: 8,409 shares worth $670K. The stake represents 0.72% of the portfolio and ranks #45 among its holdings.

106 funds tracked by Wall St. Rank hold MNPR as of Q3 2026.

  • Verdad Advisers held 8,409 shares of Monopar Therapeutics worth $670K as of Q3 2026.
  • Monopar Therapeutics was a new Verdad Advisers position in Q3 2026.
  • Monopar Therapeutics made up 0.72% of Verdad Advisers's portfolio in Q3 2026, its #45 holding.
  • 106 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q3 2026.

Based on Verdad Advisers's 13F filing for Q3 2026, filed 16 Nov 2026.